Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE

被引:21
作者
Velikyan, Irina [1 ,2 ,3 ]
Xu, Hui [2 ]
Nair, Manoj [2 ]
Hall, Hakan [3 ]
机构
[1] Univ Uppsala Hosp, Ctr Med Imaging, PET Ctr, SE-75185 Uppsala, Sweden
[2] Uppsala Univ, Dept Radiol Oncol & Radiat Sci, SE-75185 Uppsala, Sweden
[3] Uppsala Univ, Dept Med Chem, Preclin PET Platform, SE-75183 Uppsala, Sweden
关键词
Ga-67/68]Ga-DOTA-TOC; Ga-67/68]Ga-DOTA-TATE; Biodistribution; Positron emission tomography; Radiochemistry; POSITRON-EMISSION-TOMOGRAPHY; RADIOLABELED SOMATOSTATIN ANALOGS; RADIONUCLIDE-THERAPY; NEUROENDOCRINE TUMORS; GA-68-DOTATATE PET; MONKEY BRAIN; RECEPTOR; LOCALIZATION; GA-68-DOTA-TYR(3)-OCTREOTIDE; SCINTIGRAPHY;
D O I
10.1016/j.nucmedbio.2011.12.010
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives: Various radionuclide-labeled somatostatin analogues are used currently for diagnosis and therapy of neuroendocrine tumors. In particular, [Ga-68]Ga-DOTA-TOC is commonly used for diagnosis, while [Lu-177]Lu-DOTA-TATE is used for therapy. With the development of theranostics and personalized medicine where the imaging diagnosis is tailored to the subsequent radiotherapy, it is of paramount importance to investigate the relevance of the ligand exchange. The aim of this study was to compare binding capacity of [Ga-67/68]Ga-DOTA-TOC ([Ga-67/68]Ga-N-(4,7,10-(tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetyl-D-Phe-c[Cys-D-Tyr-Trp-Lys-Thr-Cys]-Thr(ol)) and [Ga-67/68]Ga-DOTA-TATE ([Ga-67/68]Ga-N-(4,7, 10-(tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetyl-D-Phe-c[Cys-D-Tyr-Trp-Lys-Thr-Cys]-Thr) in vitro in monkey brain cryosections and in vivo in the rat, where, in contrast to transfected cell lines, there is a heterogeneous distribution of somatostatin receptor (SSTR) subtypes. The influence of various production methods of [Ga-68]Ga-DOTA-TOC and [Ga-68]Ga-DOTA-TATE on the biological performance of the tracers was also studied. Material and Methods: [Ga-67]Ga-DOTA-TOC, [Ga-68]Ga-DOTA-TOC, [Ga-67]Ga-DOTA-TATE and [Ga-68]Ga-DOTA-TATE were synthesized including preconcentration and purification of the generator eluate. The binding of the radioligands was assessed in vitro using autoradiography on cryosections of Rhesus monkey brains and in vivo/ex vivo using organ distribution studies in rats. Results and Discussion: The tracer production method was improved in terms of higher robustness, simplification and good manufacturing practice (GMP) relevance. The synthesis variation did not influence the biological performance of the tracers. There was no statistically significant difference observed in the binding of [Ga-67/68]Ga-DOTA-TOC and [Ga-67/68]Ga-DOTA-TATE either in brain cortex in vitro or in rat biodistribution and uptake in SSTR-positive tissues such as pancreas, adrenals and pituitary. The uptake in these organs was precluded by the excess of octreotide (Sandostatin). The 10-fold higher affinity to SSTR2 of DOTA-TATE as compared to DOTA-TOC known from studies in transfected cells was reflected in a slightly more intense binding of [Ga-67/68]Ga-DOTA-TATE than of [Ga-67/68]Ga-DOTA-TOC in the monkey brain sections in vitro, but not in vivo in the rat. Conclusion: A robust Ga-68-labeling method was introduced. The difference in the uptake of [Ga-67/68]Ga-DOTA-TOC and [Ga-67/68]Ga-DOTA-TATE in SSTR2-positive organs was not statistically significant either in vitro in tissue studies or in vivo/ex vivo in rat experiments. The results indicate that the more complex environment in vitro and in vivo diminishes the difference observed in transfected cell line binding. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:628 / 639
页数:12
相关论文
共 46 条
  • [1] What can gallium-68 PET add to receptor and molecular imaging?
    AL-Nahhas, Adil
    Win, Zarni
    Szyszko, Teresa
    Singh, Aviral
    Khan, Sameer
    Rubello, Domenico
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (12) : 1897 - 1901
  • [2] Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
    Antunes, P.
    Ginj, M.
    Zhang, H.
    Waser, B.
    Baum, R. P.
    Reubi, J. C.
    Maecke, H.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (07) : 982 - 993
  • [3] Optimal buffer choice of the radiosynthesis of 68Ga-Dotatoc for clinical application
    Bauwens, Matthias
    Chekol, Rufael
    Vanbilloen, Hubert
    Bormans, Guy
    Verbruggen, Alfons
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2010, 31 (08) : 753 - 758
  • [4] SOMATOSTATIN BINDING-SITES IN HUMAN AND MONKEY BRAIN - LOCALIZATION AND CHARACTERIZATION
    BEAL, MF
    TRAN, VT
    MAZUREK, MF
    CHATTHA, G
    MARTIN, JB
    [J]. JOURNAL OF NEUROCHEMISTRY, 1986, 46 (02) : 359 - 365
  • [5] Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion:: a phase I study
    Bodei, L
    Cremonesi, M
    Zoboli, S
    Grana, C
    Bartolomei, M
    Rocca, P
    Caracciolo, M
    Mäcke, HR
    Chinol, M
    Paganelli, G
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (02) : 207 - 216
  • [6] Breeman WAP, 2002, J NUCL MED, V43, P1650
  • [7] Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives
    Breeman, WAP
    de Jong, M
    Kwekkeboom, DJ
    Valkema, R
    Bakker, WH
    Kooij, PPM
    Visser, TJ
    Krenning, EP
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (09) : 1421 - 1429
  • [8] 68Ga-labeled DOTA-Peptides and 68Ga-labeled Radiopharmaceuticals for Positron Emission Tomography: Current Status of Research, Clinical Applications, and Future Perspectives
    Breeman, Wouter A. P.
    de Blois, Erik
    Chan, Ho Sze
    Konijnenberg, Mark
    Kwekkeboom, Dik J.
    Krenning, Eric P.
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2011, 41 (04) : 314 - 321
  • [9] Binding properties of somatostatin receptor subtypes
    Bruns, C
    Raulf, F
    Hoyer, D
    Schloos, J
    Lubbert, H
    Weckbecker, G
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1996, 45 (08): : 17 - 20
  • [10] Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide:: The experience of the European Institute of Oncology Group
    Chinol, M
    Bodei, L
    Cremonesi, M
    Paganelli, G
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2002, 32 (02) : 141 - 147